Literature DB >> 10743284

Simian virus 40, poliovirus vaccines, and human cancer: research progress versus media and public interests.

J S Butel1.   

Abstract

From 1955 through early 1963, millions of people were inadvertently exposed to simian virus 40 (SV40) as a contaminant of poliovirus vaccines; the virus had been present in the monkey kidney cultures used to prepare the vaccines and had escaped detection. SV40 was discovered in 1960 and subsequently eliminated from poliovirus vaccines. This article reviews current knowledge about SV40 and considers public responses to reports in the media. SV40 is a potent tumour virus with broad tissue tropism that induces tumours in rodents and transforms cultured cells from many species. It is also an important laboratory model for basic studies of molecular processes in eukaryotic cells and mechanisms of neoplastic transformation. SV40 neutralizing antibodies have been detected in individuals not exposed to contaminated poliovirus vaccines. There have been many reports of detection of SV40 DNA in human tumours, especially mesotheliomas, brain tumours and osteosarcomas; and DNA sequence analyses have ruled out the possibility that the viral DNA in tumours was due to laboratory contamination or that the virus had been misidentified. However, additional studies are necessary to prove that SV40 is the cause of certain human cancers. A recently published review article evaluated the status of the field and received much media attention. The public response emphasized that there is great interest in the possibility of health risks today from vaccinations received in the past.

Entities:  

Keywords:  NASA Discipline Regulatory Physiology; NASA Program Biomedical Research and Countermeasures; Non-NASA Center

Mesh:

Substances:

Year:  2000        PMID: 10743284      PMCID: PMC2560680     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Immunisation safety: a priority of the World Health Organization's Department of Vaccines and Biologicals.

Authors:  P Duclos; C A Hofmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Presence of JC virus DNA in the tumor tissue and normal mucosa of patients with sporadic colorectal cancer (CRC) or with positive family history and Bethesda criteria.

Authors:  Alex Vilkin; Ziv Ronen; Zohar Levi; Sara Morgenstern; Marisa Halpern; Yaron Niv
Journal:  Dig Dis Sci       Date:  2011-08-10       Impact factor: 3.199

Review 3.  Placental Models for Evaluation of Nanocarriers as Drug Delivery Systems for Pregnancy Associated Disorders.

Authors:  Louise Fliedel; Khair Alhareth; Nathalie Mignet; Thierry Fournier; Karine Andrieux
Journal:  Biomedicines       Date:  2022-04-19

4.  Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen.

Authors:  Ying-Hui Zhang; Klaas Kooistra; Alexandra Pietersen; Jennifer L Rohn; Mathieu H M Noteborn
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Production of avian influenza virus vaccine using primary cell cultures generated from host organs.

Authors:  Mustafeez Mujtaba Babar; Muhammad Suleman Riaz; Najam-us-Sahar Sadaf Zaidi; Farhan Afzal; Muhammad Sabir Farooq
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-21       Impact factor: 3.346

Review 6.  Urinary immunoglobulins in viral diagnosis: An overview.

Authors:  Sreelekshmy Mohandas; Sudeep Balan; Devendra T Mourya
Journal:  Indian J Med Res       Date:  2022-01       Impact factor: 5.274

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.